Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
A look at big oncology deals since 2016 finds outright success stories hard to come by.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
Will a TIGIT refocus see the stars finally align for the partners?
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.